New trial aims to keep myeloma at bay after transplant
NCT ID NCT07409454
Summary
This study is testing a drug called CM336, a targeted antibody, as a maintenance therapy for people with multiple myeloma who have recently had a stem cell transplant. The goal is to see if this drug can help control the disease by eliminating any remaining cancer cells and prevent it from coming back. The trial will involve 20 newly diagnosed patients who still show tiny amounts of cancer after their transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.